Obesity pill race heats up

CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.